



**scleroderma**  
**victoria**

**Scleroderma Victoria Incorporated**  
**ANNUAL REPORT 2022 – 2023**

Scleroderma Victoria Inc.  
St. Vincent's Hospital,  
41 Victoria Parade,  
FITZROY VIC 3065  
Phone: 03 9231 3651

[Scleroderma Victoria](https://www.scleroderma.vic.gov.au/)

*Registration Incorporation No. A0017798A*

ABN AND ACNC - 45 674 166 348



scleroderma **victoria**

## **Agenda**

### **43rd Annual General Meeting - November 18, 2023**

- 1.** Welcome and Introductions
- 2.** Guest Speaker - Dr Wendy Stevens
- 3.** Business of the AGM
- 4.** Apologies
- 5.** Confirmation of minutes of the 42nd AGM held on 19 November 2022
- 6.** President's and Treasurer's Reports
- 7.** Receive, consider and adopt the 30 June 2023 Financial Statements
- 8.** Election of Office Bearers and Committee Members for 2023/24
- 9.** Appointment of Auditors for the year ending 30 June 2024
- 10.** Other business without notice

# Minutes – 42nd Annual General Meeting of Scleroderma Victoria Inc

Saturday 19 November 2022



<b>Time</b>	<b>2:00 to 4:00 pm</b>
<b>Venue</b>	Google Meet Online
<b>Attendees</b>	Amanda Lawrie-Jones (President), Louise Inglese (Vice-President), Iain Pizzey (Treasurer), Jennene Caton (Secretary), Belinda McMaster, Mark Langhorn, Georgie Waters, Bridget Naughton, Jane Rhyder, Andrew Rhyder, Janelle Blight, Liz Walford, Lynette Slade, Gilbert McGill, Heather Holloway, Brenda Condon, Kathleen Phelan, Tara Hanaveld, Sandra Varodic, Ellen Kessler, Irene Tung, Gail Jerrett, Denise Eastman, Tania Ciotti, Angela Bull and Jenny Sward
<b>Apologies</b>	Yvonne Hoffmann, Shirley Hess, Dianne Lacey, Robyn Sims, Don and Pina D'Alessandro
<b>Minutes</b>	Jennene Caton
<b>Chairperson</b>	Amanda Lawrie-Jones

## Meeting opened 2.00 pm

Amanda welcomed everyone to the AGM and introduced all the existing Committee members. Amanda introduced our guest speaker; Dr Alannah Quinlivan.

### **i. Guest Speaker – Dr Laura Ross**

Dr Quinlivan is our Harrison Pennicott scholarship recipient. She spoke about her current study; "Gastrointestinal Involvement in Systemic Sclerosis"

### **ii. Business of the 2022 AGM – Confirmation of 2021 minutes**

Amanda invited Jennene to read out the list of apologies. It was moved that the minutes from the 41st AGM dated 20th November 2021 were confirmed as a true and accurate record of proceedings and were signed by the President.

**Moved: Mark Langford Seconded: Liz Walford**

### **iii. Presidents Report**

Covid challenges have limited our fundraising ability and our support groups activities. We have been fortunate that we have been able to continue our Virtual Education Sessions in 2022. This project is supported by a grant from Jansen Pharmaceuticals. This has allowed us to record some of our sessions and share on our You Tube channel. These sessions will continue into 2023.

Unfortunately, we lost some very dear members of our Scleroderma Community this year; Nia Sims, Gene Swinstead, Lindon Chipman and Luisa D'Alessandro.

We have two new committee members since our last AGM; Janelle Blight (support groups) and Georgie Waters (newsletter editor).

Our World Scleroderma Luncheon was a great success again this year. Our thanks to The London Tavern Hotel who offered us great food, service and venue. Thank you to Dyson Heppell who was able to attend. From 2023 onwards this event will be known as the *Gene Swinstead Memorial Luncheon* in honour of Gene, who we lost shortly after the event. He was the organiser of this event for several years.

We have two new scleroderma nurses; Louise at St Vincent's hospital and Roxanne at the Monash Medical Centre.

Our memberships numbers have mostly stayed the same this year at 334.

Annette Johnston in Tasmania was able to help a member purchase an oxygen concentrator with funds from the Brett Johnston memorial fund.

We have had a change of social media company; we now use Hello Media.

We have also joined Rare Voices which will assist us with advocacy.

Finally, Amanda thanked the outgoing committee for their hard work during the year.

Amanda then asked for someone to move her Presidents report.

**Moved:** Liz Walford      **Seconded:** Jane Rhyder

### **iv. Receive, consider and adopt the 30 June 2022 Financial Statements**

Iain Pizzey presented audited 30<sup>th</sup> June 2022 Financial Statements along with his Treasurers report. Iain summarised these reports for the meeting. Covid-19 continues to impact upon our fundraising activities. Our income was \$99,540 which was a small decrease on last financial year. Our expenses were \$116,099, due to our funding of the two hospitals (\$30K) and \$30K to the Harrison Pennicott Scholarship. This gave us a deficit of \$16,559, this result was mainly due to unrealised investment losses of \$17,633. We also received \$5,000 grant funding

from the Dept. Health and Human Services (DHHS) for printing of our newsletter throughout the year. Iain thanked Jennene for again applying for this grant which will continue to pay for our newsletter into the next two financial years (\$5K per year, total of \$10K). We also received \$2K from William Angliss and \$35K from the Shine Bright Gala Ball. Membership numbers as of 30 June 2022 was 323 (2021: 335), a decrease of 12 from 2021. We continue to work towards our membership target of 400.

Iain thanked Kylie Byrne as the signing partner from Pitcher Partners (our pro-bono auditors) for auditing our financials again this year.

Iain also informed the meeting that in accordance with the requirements of the Associations Incorporation Reform Act 2012, he and the President declared that the 30 June 2022 Financial Statements presented at the meeting, give a true and fair view of the financial performance and position of Scleroderma Victoria Incorporated during and at the end of year ended 30 June 2022.

There being no questions, it was moved that the Treasurers Report, including the audited 30 June 2022 Financial Statements be accepted;

**Moved:** Bridget Naughton      **Seconded:** Louise Inglese

#### **v. Election of Office Bearers and Committee Members**

Amanda declared all positions on the Committee were vacant. As no new nominations were received, the existing committee were re-elected unopposed.

Amanda will update our website to reflect our new committee which will be as follows;

<b>Position</b>	<b>Name</b>	<b>Nominated</b>	<b>Seconded</b>
<b>President</b>	Amanda Lawrie-Jones	Jennene Caton	Liz Walford
<b>Vice President</b>	Louise Inglese	Belinda McMaster	Janelle Blight
<b>Treasurer</b>	Iain Pizzey	Amanda Lawrie-Jones	Liz Walford
<b>Secretary</b>	Jennene Caton	Amanda Lawrie-Jones	Belinda McMaster

Position	Name	Nominated	Seconded
Ordinary Committee Members	Belinda McMaster	Jennene Caton	Janelle Blight
Ordinary Committee Members	Mark Langhorn	Jennene Caton	Jane Rhyder
Ordinary Committee Members	Georgie Waters	Amanda Lawrie-Jones	Iain Pizzey
Ordinary Committee Members	Janelle Blight	Jennene Caton	Liz Walford

**vi. Appointment of Auditors for the year ending 30 June 2023**

Iain stated that as our income is under \$250K we actually don't need to be audited each year, however it is good governance to do so. He moved that the existing Auditors, Pitcher Partners, who have completed the audit of the 30 June 2022 Financial Statements be re-elected as our Auditors for the year ending 30 June 2023.

**Moved:** Iain Pizzey

**Seconded:** Andrew Rhyder

**vii. Business without notice**

Amanda thanked Georgie Waters for producing our newsletter. She also thanked Leesa Pennicott who is hosting the second Shine Bright Gala Ball tonight. Amanda thanked all attendees at today's meeting.

There being no other business, Amanda declared the meeting closed at 4.07pm.



.....

Amanda Lawrie-Jones

**President**

Date: Nov 17, 2023



scleroderma victoria

## President's Report for 30 June 2023

Scleroderma Victoria's Committee are incredibly dedicated to bringing their all to supporting our community, and this has been no different for 2023.

We would like to welcome our newest Committee Member Hannah Kielbasa that joined us throughout the year and look forward to having her also make her mark in making a difference. May Adams is also a new addition, with her wonderful expertise in doing our newsletter and has been a delight to work with. We thank Georgie Waters for her time as newsletter editor and wish her well in her new endeavours.

If we reflect on one of the positives that Covid brought us, it was the Virtual Education Sessions. It is hard to believe that we started these weekly during our Victorian lockdowns, and here we are almost 4 years on continuing them on a monthly basis. This year's topic highlights were the Research from Harrison Pennicott Scholarship recipient Alanah Quinlivan on Gastrointestinal Involvement, Dr Amanda Saracino on Scleroderma and the Skin, and Scleroderma and the Workplace with Hall & Wilcox Partner Fay Calderone. There were many more delights in our 2023 series, and we hope that you enjoyed them as much as we did. We would also like to extend our thanks to Janssen Pharmaceuticals in providing us with an Education Grant to assist us with costs of guest speakers and recording the sessions where possible.

Our face to face support groups took some time to kick-start again in 2023, but here's to hoping that we can continue to grow them and expand our reach for support across the state. It is great to see the other states that we support, such as Tasmania, South Australia and Western Australia are also still having get together and some fun along the way.

We continue to support the Scleroderma Nurses with funding at both St Vincent's and Monash Hospitals and know this is of high value to our scleroderma community.

World Scleroderma Awareness month and day were as successful as always, and we would like to extend our sincere thanks to the London Tavern Hotel in their generosity for making the day so memorable. It was so great to have Dr Nava Ferdowsi as our guest speaker to share some new research on scleroderma. Our Live Auction on the day was also another highlight and thank you to everyone who contributed and donated items - especially our wonderful Ambassador Dyson Heppell.

Our financial membership base has largely been the same over the past few years, although we have seen a slight drop in 2023. This impacts our advocacy and Grant request proposals where we need to declare our membership numbers.

I'd like to personally thank all Scleroderma Victoria committee members for their incredible dedication and acknowledge their amazing efforts in providing the best support, education, and research opportunities that we can. Thank you to our members, without you we would not be able to do what we do.

***Together we can make a difference.***

**Amanda Lawrie-Jones**

**President – Scleroderma Victoria**

November 15, 2023





scleroderma victoria

## Treasurer's Report for 30 June 2023

I am pleased to present the Treasurer's Report for the year ended 30 June 2023, incorporating the 30 June 2023 Financial Statements.

### Income

Our income for the year was \$172,955 (2022: \$99,540), an increase of \$73,415 or 73% from the previous year. Included in our income for the year was:

- Membership Subscriptions of \$4,818 (2022: \$6,145) a \$1,327 decrease relating to a decrease in Members from 323 to 300.
- General & Memorial Donations of \$54,329 (2022: \$20,035), increase of \$34K or 171%.
- Fundraising activities raised \$24,428 (2022: \$29,846).
- DHHS Health Condition Support Grant Band 1 of \$5K (2022: \$5K).
- Distribution from Shine Bright Gala of \$46,375 (2022: \$35,000),
- Donation from Melbourne Racing Club Foundation of \$5K,
- Distribution from William Angliss (Victoria) Charitable Fund of \$2K, (2022: \$2K), and
- Unrealised investment gains of \$29,387 (2022: Losses of \$17,633).

### Expenses

Our expenses for the year amounted to \$99,283 (2022: \$116,099), a decrease of \$16,816 or 14% from FY2022 and included the following major items for the year:

- Funding to support Scleroderma health care at St Vincent's Hospital of \$15K (2022: \$15K).
- Funding to support Scleroderma health care at Monash Medical Hospital of \$15K (2022: \$15K).
- Funding of Harrison Pennicott PhD Scholarship at University of Melbourne of \$30K (2022: \$30K) supporting Scleroderma research.

- Producing Scleroderma Victoria newsletter of \$7,190 (2022: \$6,859), and
- Funding SPIN (Scleroderma Patient-centred Intervention Network) activities of \$5K (2022: \$5K).

## **Overall Result**

The overall result for the Foundation was a surplus of \$73,672 (2022: deficit of \$16,559). This result was mainly due to the increase in General & Memorial donations, increased in fundraising income and an increase in unrealised investment gains.

Scleroderma Victoria continued to fund the scleroderma nurses at St Vincent's and Monash Medical centre totalling \$30,000 and University of Melbourne undertaking Scleroderma research for \$30,000.

We have continued to increase our Social Media exposure and platforms and linking in with World Scleroderma Day on 29 June. Our annual Scleroderma Day lunch was successfully held in early June and raised \$9,764 and we received \$46,375 from the Shine Bright Gala event that was so well organised by Leesa Pennicott.

## **Expenses**

Scleroderma Victoria contributed \$30,000 to assist the Scleroderma nurses at St Vincent's Hospital and Monash Medical Centre. Membership numbers at 30 June 2023 were 300 (2022: 323), a decrease of 23 from 2022. We continued to work towards our membership target of 400.

## **Recent Funding applications**

In June 2023, the Foundation again applied to be considered for funding from The William Angliss (Victoria) Charitable Fund. We have yet to hear if we were successful in 2023 but we have been successful on all previous occasions and in December 2022 we received \$2,000.

On 20 October 2021, we were successful with our application for funding under the 2021-2023 Health Condition Support Grants program. We received \$5,000 in FY2023 to offset the costs of producing and distributing our newsletter to our Members.

## **Recent Research funding**

On 7 September 2019, the Committee agreed to support and fund a \$105K University of Melbourne PhD Scholarship Programme into systemic sclerosis (scleroderma) for 3.5 years. We have so far paid \$90K to support this

important research work as a third payment of \$30K was made in December 2022 with the balance of \$15K to be paid in December 2023.

## **Investments**

In conjunction with our Investment Advisers, Planning Partners, the Foundation invests as a cautious investor. Planning Partners, our Investment Advisers, work with us to ensure we have the most appropriate Asset allocation for our Investment Portfolio.

Whilst our financial position remains sound, we continue to apply for Grants and seek to increase our fundraising initiatives to increase our financial strength to enable us to continue to support the excellent work of scleroderma nurses and to continue our contributions to Scleroderma Australia to assist with funding medical research. Our investments are 'set aside' to be used to fund appropriate medical research regarding scleroderma in the future and therefore we should avoid using them to pay for administration expenses.

Thank you

I would like to thank Kylee Byrne from Pitcher Partners, our Auditors, who has continued to support us and audited the 30 June 2023 Financial Statements pro bono.

I would also like to thank our President Amanda Lawrie-Jones, our Office Administrator Jennene Caton, all Members of the Committee during the year and all our volunteers, for their efforts and the time they have given to the Foundation.

I look forward to the next 12 months.

**Iain Pizzey CA, Honorary Treasurer**

15 November 2023

# SCLERODERMA VICTORIA INCORPORATED

## FINANCIAL REPORT FOR THE YEAR ENDED 30 JUNE 2023

<b>Contents</b>	<b>Page</b>
Statement of Profit and Loss and Other Comprehensive Income	2
Statement of Financial Position	3
Statement of Changes in General Funds	4
Notes to the Financial Statements	5-13
Declaration by the Committee of Management	14
Independent Auditor's Report	15-17
Unaudited Detailed Income Statement	18-19

## SCLERODERMA VICTORIA INCORPORATED

### STATEMENT OF PROFIT AND LOSS AND OTHER COMPREHENSIVE INCOME FOR THE YEAR ENDED 30 JUNE 2023

	Notes	2023 \$	2022 \$
Revenue	2	172,955	99,540
Expenses	2	<u>(99,283)</u>	<u>(116,099)</u>
Total Comprehensive Surplus/(Deficit) for the year		73,672	(16,559)
Accumulated funds at the beginning of the year		364,743	381,302
Accumulated funds at the end of the year	8	<u>438,415</u>	<u>364,743</u>

The above Statement of Profit and Loss and Other Comprehensive Income is to be read in conjunction with the notes to the financial statements as set out on pages 5 to 13.

## SCLERODERMA VICTORIA INCORPORATED

### STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2023

	Notes	2023 \$	2022 \$
<b>CURRENT ASSETS</b>			
Cash assets	3	110,179	84,581
Receivables	4	5,688	2,458
Investments	5	348,284	308,347
Prepayment		5,000	-
<b>TOTAL CURRENT ASSETS</b>		469,151	395,386
<b>NON CURRENT ASSETS</b>			
Fixed Assets	6	-	-
Intangible Assets		179	167
<b>TOTAL NON CURRENT ASSETS</b>		179	167
<b>TOTAL ASSETS</b>		469,330	395,553
<b>CURRENT LIABILITIES</b>			
Payables	7	2,209	4,104
Income in Advance		2,000	-
<b>TOTAL CURRENT LIABILITIES</b>		4,209	4,104
<b>TOTAL LIABILITIES</b>		4,209	4,104
<b>NET ASSETS</b>		465,121	391,449
<b>GENERAL FUNDS</b>			
Accumulated Funds	8	438,415	364,743
Specific Fund	9	26,706	26,706
<b>TOTAL GENERAL FUNDS</b>		465,121	391,449

The above Statement of Financial Position should be read in conjunction with the notes to the financial statements as set out on pages 5 to 13.

# SCLERODERMA VICTORIA INCORPORATED

## STATEMENT OF CHANGES IN GENERAL FUNDS FOR THE YEAR ENDED 30 JUNE 2023

	NOTES	2023 \$	2022 \$
<b>General Funds</b>			
Opening Balance		364,743	381,302
Result for the year		73,672	(16,559)
<b>Closing Balance</b>	8	<u>438,415</u>	<u>364,743</u>

The above Statement of Changes in General Funds should be read in conjunction with the notes to the financial Statements as set out on pages 5 to 13.

# SCLERODERMA VICTORIA INCORPORATED

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2023

### 1 STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

#### (a) Basis of Preparation

In the opinion of the Committee, Scleroderma Victoria Incorporated (“Scleroderma Victoria”) is not a reporting entity. The financial statements of Scleroderma Victoria have been prepared as a special purpose financial report in order to satisfy the financial reporting requirements of the *Victorian Associations Incorporation Reform Act 2012* (and its associated Regulations) and the *Australian Charities and Not-for-profits Commission Act 2012*.

The financial report has been prepared in accordance with the requirements of the *Victorian Associations Incorporation Reform Act 2012* (and its associated Regulations), the *Australian Charities and Not-for-profit Commission Act 2012* and applicable Accounting Standards, with the exception of:

AASB 7: Financial Instruments: Disclosure  
AASB 101: Presentation of Financial Statements  
AASB 107: Cashflow Statements  
AASB 124: Related Party Disclosures

The financial report has been prepared on the basis of historical costs, modified by valuing investments at fair value.

The accounting policies have been consistently applied and are consistent with those of the previous year.

#### (b) Revenue

Scleroderma Victoria recognises membership fees, donations and other income when received.

Interest, dividends and other distributions from investments are recognised as income when received.

#### (c) Trade and Other Receivables

Trade and other receivables are recognised and carried at original invoice amount.

#### (d) Trade and Other Payables

Trade and other payables are included at cost and represent liabilities for goods and services provided to Scleroderma Victoria prior to the end of the financial year.



# SCLERODERMA VICTORIA INCORPORATED

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2023

### 1 STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES (continued)

#### (e) Cash and Cash Equivalents

Cash and cash equivalents in the Statement of Financial Position comprise cash at bank.

#### (f) Investments

Investments are held through unlisted managed funds that are recorded at fair value. If the underlying investments of the fund are traded in active markets, fair value is determined with reference to quoted market prices at the end of the reporting period. If the underlying investments are not traded in active markets, fair value is determined at close of business as at the reporting date.

Investments are to be used to fund appropriate and approved medical research.

#### (g) Intangible Assets

Intangible Assets relates to the registration of the business names Sunflower Hero and Get Behind the Beard with ASIC.

#### (h) Taxes

##### (i) Income Tax

The Australian Taxation Office has confirmed that Scleroderma Victoria Incorporated is a public benevolent institution and has been endorsed as a Charitable Institution and is income tax exempt in accordance with Subdivision 50-B of the Income Tax Assessment Act 1997.

##### (ii) Goods and Services Tax (GST)

Revenues and expenses are recognised net of the amount of Goods and Services Tax (GST), except where the amount of GST incurred is not recoverable from the Australian Taxation Office.

Receivables and payables are stated inclusive of GST. The net amount of GST recoverable from, or payable to, the Australian Taxation Office is included as part of receivables or payables in the Statement of Financial Position.

#### (i) Financial instruments

##### *Initial recognition and measurement*

Financial assets and financial liabilities are recognised when Scleroderma Victoria becomes a party to the contractual provisions of the instrument. For financial assets, this is equivalent to the date that Scleroderma Victoria commits itself to either the purchase or sale of the asset (i.e. trade date accounting is adopted).

# SCLERODERMA VICTORIA INCORPORATED

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2023

### 1 STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

#### (i) Financial instruments (continued)

Financial instruments are initially measured at fair value adjusted for transaction costs, except where the instrument is classified as fair value through profit or loss, in which case transaction costs are immediately recognised as expenses in profit or loss.

##### *Classification of financial assets*

Financial assets recognised by Scleroderma Victoria are subsequently measured in their entirety at either amortised cost or fair value, subject to their classification and whether Scleroderma Victoria irrevocably designates the financial asset on initial recognition at fair value through other comprehensive income (FVtOCI) in accordance with the relevant criteria in AASB 9.

Financial assets not irrevocably designated on initial recognition at FVtOCI are classified as subsequently measured at amortised cost, FVtOCI or fair value through profit or loss (FVtPL) on the basis of both:

- (a) Scleroderma Victoria's business model for managing the financial assets; and
- (b) the contractual cash flow characteristics of the financial asset.

##### *Classification of financial liabilities*

Financial liabilities classified as held-for-trading, contingent consideration payable by Scleroderma Victoria for the acquisition of a business, and financial liabilities designated at FVtPL, are subsequently measured at fair value. All other financial liabilities recognised by Scleroderma Victoria are subsequently measured at amortised cost.

##### *Trade and other receivables*

Trade and other receivables arise from Scleroderma Victoria's transactions with its customers and are normally settled within 30 days.

Consistent with both Scleroderma Victoria's business model for managing the financial assets and the contractual cash flow characteristics of the assets, trade and other receivables are subsequently measured at amortised cost.

# SCLERODERMA VICTORIA INCORPORATED

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2023

### 1 STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

#### (i) Financial instruments (continued)

Impairment of financial assets

The following financial assets are tested for impairment by applying the 'expected credit loss' impairment model:

- (a) debt instruments measured at amortised cost;
- (b) debt instruments classified at fair value through other comprehensive income; and
- (c) receivables from contracts with customers and contract assets.

Scleroderma Victoria applies the simplified approach under AASB 9 to measuring the allowance for credit losses for both receivables from contracts with customers and contract assets. Under the AASB 9 simplified approach, Scleroderma Victoria determines the allowance for credit losses for receivables from contracts with customers and contract assets on the basis of the lifetime expected credit losses of the financial asset. Lifetime expected credit losses represent the expected credit losses that are expected to result from default events over the expected life of the financial asset.

There has been no change in estimation techniques or significant assumptions made during the reporting period.

#### (j) Comparative Note

Where necessary, comparative information has been reclassified and repositioned for consistency with current year disclosures.

## SCLERODERMA VICTORIA INCORPORATED

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2023

#### 2 RESULT FOR THE YEAR

The result has been determined after:

	2023	2022
	\$	\$
(i) Crediting as Revenue:		
Membership	4,818	6,145
Donations	54,329	20,035
Fundraising activities	14,664	7,496
World Scleroderma Day Lunch	9,764	22,350
Distribution from William Angliss	2,000	2,000
Donation – Melbourne Racing Club		
Foundation	5,000	-
Janssen Australia Sponsorship	1,618	1,405
Investment Income – Net	29,387	109
Grant from Vic Government Department Of		
Health & Human Services	5,000	5,000
Shine Bright Gala Event	46,375	35,000
	<u>172,955</u>	<u>99,540</u>
(ii) Charging as an Expense:		
Administration Support	6,900	6,900
Funding SPIN activities	5,000	5,000
Funding paid to Hospitals to support		
Scleroderma Health Care	30,000	30,000
Insurances	1,363	1,085
Funding of Harrison Pennicott PhD		
Scholarship	30,000	30,000
Seminar & Fundraising Expenses	822	2,025
Office Expenses	6,416	8,152
Design, Print & Post Newsletter costs	7,190	6,859
Scleroderma Australia Membership	1,615	1,675
Social Media	7,672	4,380
Unrealised Investment Losses	-	17,633
Investment Adviser Expenses	2,305	2,390
	<u>99,283</u>	<u>116,099</u>

## SCLERODERMA VICTORIA INCORPORATED

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2023

#### 3 CASH ASSETS

The balance of cash at bank consists of the following Bank Accounts.

	2023	2022
	\$	\$
Operating Bank Account	80,331	54,687
Kerry McDonald Equipment Fund	3,142	3,188
Brett Johnson Memorial Account	26,706	26,706
	110,179	84,581
	110,179	84,581
<b>4 RECEIVABLES</b>		
Other Debtors	1,137	-
Other Debtors - PayPal	4,247	1,934
GST Receivable	304	524
	5,688	2,458
	5,688	2,458
<b>5 INVESTMENTS</b>		
Managed Funds and Listed Trusts	323,407	284,697
Cash Holdings and Term Deposit	24,877	23,650
	348,284	308,347
	348,284	308,347
<b>6 FIXED ASSETS</b>		
Equipment	24,381	24,381
Accumulated Depreciation	(24,381)	(24,381)
	-	-
	-	-
<b>7 PAYABLES</b>		
Creditors	1,137	2,447
Security Deposits	900	900
GST Payable	172	757
	2,209	4,104
	2,209	4,104
<b>8 GENERAL FUNDS</b>		
Retained surplus at the beginning of the financial year	364,743	381,302
Net result for the year	73,672	(16,559)
	438,415	364,743
	438,415	364,743

# SCLERODERMA VICTORIA INCORPORATED

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2023

	2023	2022
	\$	\$
<b>9 SPECIFIC FUND</b>		
Brett Johnson Memorial Account	26,706	26,706

This Fund was established in October 2016 to assist Tasmanian families that had been impacted by Scleroderma. The spending of the funds raised is managed by Ms Annette Johnson.

### 10 REMUNERATION OF AUDITORS

Pitcher Partners, the Auditors of Scleroderma Victoria, audited the 30 June 2023 Financial Statements pro bono.

### 11 SCLERODERMA VICTORIA INCORPORATED INFORMATION

Scleroderma Victoria is incorporated under the *Victorian Associations Incorporation Reform Act 2012* (and its associated regulations) and its registered address and principal place of business is St Vincent's Hospital, 41 Victoria Parade Fitzroy, Victoria 3065.

As at 30 June 2023, Scleroderma Victoria had 300 (2022: 323) Members.

### 12 SUBSEQUENT EVENTS

There has been no matter or circumstance, which has arisen since 30 June 2023 that has significantly affected or may significantly affect:

- (a) the operations, in financial years subsequent to 30 June 2023 of Scleroderma Victoria,
- (b) the results of those operations, or
- (c) the state of affairs, in financial years subsequent to 30 June 2023, of Scleroderma Victoria.

### 13 RELATED PARTY DISCLOSURES

During the year, there were transactions between Members of the Committee and Scleroderma Victoria Incorporated that related to the paying of yearly Membership Subscriptions by the Committee or Scleroderma Victoria reimbursing Members for costs they had incurred on behalf of Scleroderma Victoria.

All Committee Members are volunteers and received no remuneration for their services to Scleroderma Victoria Incorporated.

# SCLERODERMA VICTORIA INCORPORATED

## DECLARATION BY THE

### COMMITTEE OF MANAGEMENT

**30 JUNE 2023**

We, Amanda Lawrie-Jones, being the Honorary President, and Iain Pizzey being the Honorary Treasurer of Scleroderma Victoria Incorporated, ("Scleroderma Victoria ") do state on behalf of the Committee that:

- (i) Scleroderma Victoria is not a reporting entity.
- (ii) As is common for organisations of this type, it is not practicable for the Committee to maintain effective independent controls over donations and other fundraising activities prior to their entry in the accounting records. Accordingly, the amounts detailed in relation to receipts were limited to amounts recorded in the books of account.
- (iii) In the opinion of the Committee, the attached financial report shows a true and fair view of the financial position of Scleroderma Victoria as at 30 June 2023 and the results of its operations for the year ended on that date in accordance with Australian Accounting Standards, the *Victorian Associations Incorporation Reform Act 2012* (and its associated Regulations) and the *Australian Charities and Not-for-profits Commission Act 2012*;
- (iv) In the opinion of the Committee, meetings of the Committee of Management were held during the year ended 30 June 2023 in accordance with the rules of Scleroderma Victoria
- (v) The Committee is of the opinion that Scleroderma Victoria will be able to pay its debts as and when they fall due.



---

**Amanda Lawrie-Jones**  
Honorary President

15 November 2023



---

**Iain Pizzey**  
Honorary Treasurer

15 November 2023

**SCLERODERMA VICTORIA INCORPORATED**  
**45 674 166 348**

**INDEPENDENT AUDITOR'S REPORT**  
**TO THE MEMBERS OF**  
**SCLERODERMA VICTORIA INCORPORATED**

**Report on the Audit of the Financial Report**

*Opinion*

We have audited the financial report of Scleroderma Victoria Incorporated “the Registered Entity”, which comprises the statement of financial position as at 30 June 2023, the statement of comprehensive income and statement of changes in general funds for the year then ended, and notes to the financial statements, including a summary of significant accounting policies, and the responsible entities’ declaration.

In our opinion the financial report of Scleroderma Victoria Incorporated has been prepared in accordance with Division 60 of the *Australian Charities and Not-for-Profits Commission Act 2012*, including:

- (a) giving a true and fair view of the Registered Entity’s financial position as at 30 June 2023 and of its financial performance for the year ended; and
- (b) complying with Australian Accounting Standards to the extent described in Note 1, and Division 60 the *Australian Charities and Not-for-profits Commission Regulations 2022*.

*Basis for opinion*

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor’s Responsibilities for the Audit of the Financial Report section* of our report. We are independent of the Registered Entity in accordance with the *Australian Charities and Not-for-profits Commission Act 2012* “ACNC Act” and the ethical requirements of the Accounting Professional and Ethical Standards Board’s *APES 110 Code of Ethics for Professional Accountants (including Independence Standards)* “the Code” that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

*Emphasis of Matter - Basis of Accounting*

We draw attention to Note 1 to the financial report, which describes the basis of accounting. The financial report has been prepared for the purpose of fulfilling the Registered Entity’s financial reporting responsibilities under the ACNC Act. As a result, the financial report may not be suitable for another purpose. Our opinion is not modified in respect of this matter.



**SCLERODERMA VICTORIA INCORPORATED  
45 674 166 348**

**INDEPENDENT AUDITOR'S REPORT  
TO THE MEMBERS OF  
SCLERODERMA VICTORIA INCORPORATED**

*Responsibility of the Committee of Management*

The Committee of Management of the Registered Entity are responsible for the preparation of the financial report that gives a true and fair view and have determined that the basis of preparation described in Note 1 to the financial report is appropriate to meet the requirements of the ACNC Act, the *Associations Incorporation Reform Act 2012 (and its associated regulations)* and the needs of the members. The Committee of Management responsibility also includes such internal control as the responsible entities determine is necessary to enable the preparation of a financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the Committee of Management are responsible for assessing the Registered Entity's ability to continue as a going concern, disclosing, as applicable, matters relating to going concern and using the going concern basis of accounting unless the responsible entities either intend to liquidate the Registered Entity or to cease operations, or have no realistic alternative but to do so.

*Auditor's Responsibilities for the Audit of the Financial Report*

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial report.

As part of an audit in accordance with Australian Auditing Standards, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Registered Entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by responsible entities.

SCLERODERMA VICTORIA INCORPORATED  
45 674 166 348

INDEPENDENT AUDITOR'S REPORT  
TO THE MEMBERS OF  
SCLERODERMA VICTORIA INCORPORATED

*Auditor's Responsibilities for the Audit of the Financial Report (continued)*

- Conclude on the appropriateness of responsible entities' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Registered Entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Registered Entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



K L BYRNE  
Partner



PITCHER PARTNERS  
Melbourne

15 November 2023

## SCLERODERMA VICTORIA INCORPORATED

### UNAUDITED DETAILED INCOME STATEMENT FOR THE YEAR ENDED 30 JUNE 2023

	2023	2022
	\$	\$
<b>INCOME</b>		
Donations	32,319	11,755
Memorial Donations	22,010	8,280
Distribution from William Angliss	2,000	2,000
Donation – Melbourne Racing Club Foundation	5,000	-
World Scleroderma Day Lunch	9,764	22,350
Grant – Vic Government Department of Health and Human Services	5,000	5,000
Janssen Australia Sponsorship	1,618	1,405
Donation - Brunswick United Lodge	-	-
Shine Bright Gala	46,375	35,000
Fundraising Income	14,664	7,496
Membership Income	4,818	6,145
Investment Income	29,387	109
<b>Total Income</b>	172,955	99,540
 <b>EXPENDITURE</b>		
Administration Support	6,900	6,900
Annual Return	-	60
Bank, PayPal, Merchant & mycause charges	431	896
Funding SPIN Activities	5,000	5,000
Funding paid to Hospitals to support Scleroderma Health Care	30,000	30,000
Funding Harrison Pennicott PhD Scholarship	30,000	30,000
Fundraising expenses	822	1,875
Insurances	1,363	1,085
Oxygen Concentrator Servicing	(74)	1051
Membership Subscriptions	50	794
Unrealised Investment Losses	-	17,633
Office Supplies/Expenses	288	214
Postage	600	1,235
Printing of office supplies	3,227	2,126
Printing, Design & Post Newsletter costs	7,190	6,859
Promotion & Marketing	-	455
Sunflower Hero – Renew Business name	80	-
Balance carried forward	85,877	106,183

## SCLERODERMA VICTORIA INCORPORATED

### UNAUDITED DETAILED INCOME STATEMENT FOR THE YEAR ENDED 30 JUNE 2023

	2023	2022
	\$	\$
Balance brought forward	85,877	106,183
Scleroderma Australia Membership	1,615	1,675
Seminars	-	150
Support Group meeting costs	1,419	821
Sunflower Hero's – website	345	-
Scleroderma Victoria-website hosting	50	500
Social Media	7,672	4,380
Investment Adviser Expenses	2,305	2,390
<b>Total Expenditure</b>	99,283	116,099
Net Operating Result for the year	73,672	(16,559)